Evidence map›Paper›PMID 35142995›Full record

ArticleNeurochemical research2022

3-Pyridinylboronic Acid Ameliorates Rotenone-Induced Oxidative Stress Through Nrf2 Target Genes in Zebrafish Embryos.

Fümet Duygu Üstündağ, İsmail Ünal, Ünsal Veli Üstündağ, Derya Cansız, Merih Beler, Atakan Karagöz, Hülya Kara Subaşat, A Ata Alturfan, Pınar Mega Tiber, Ebru Emekli-Alturfan

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. The Identification and Synthesis of New Sea Cucumber Peptides Leveraging Peptidomics Technology, along with their Anti-Parkinson's Disease Efficacy.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025
    Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Fümet Duygu ÜstündağInstitute of Health Sciences, Department of Biophysics, Marmara University, Istanbul, Turkey.
İsmail ÜnalInstitute of Health Sciences, Department of Biochemistry, Marmara University, Istanbul, Turkey.
Ünsal Veli ÜstündağFaculty of Medicine, Medical Biochemistry, Istanbul Medipol University, Istanbul, Turkey.
Derya CansızFaculty of Medicine, Medical Biochemistry, Istanbul Medipol University, Istanbul, Turkey.
Merih BelerInstitute of Health Sciences, Department of Biochemistry, Marmara University, Istanbul, Turkey.
Atakan KaragözInstitute of Health Sciences, Department of Biochemistry, Marmara University, Istanbul, Turkey.
Hülya Kara SubaşatGraduate School of Natural and Applied Sciences, Department of Energy, Mugla Sıtkı Kocman University, Muğla, Turkey.
A Ata AlturfanFaculty of Medicine, Department of Biochemistry, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
Pınar Mega TiberFaculty of Medicine, Department of Biophysics, Marmara University, Istanbul, Turkey.
Ebru Emekli-AlturfanFaculty of Dentistry, Department of Basic Medical Sciences, Marmara University, Istanbul, Turkey. ebruemekli@yahoo.com.ORCID http://orcid.org/0000-0003-2419-8587
Marmara University · TRIstanbul Medipol University · TRIstanbul University-Cerrahpaşa · TRMuğla University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is one of the most common forms of neurodegenerative diseases and research on potential therapeutic agents for PD continues. Rotenone is a neurotoxin that can pass the blood-brain barrier and is used to generate PD models in experimental animals. Boron is a microelement necessary for neural activity in the brain. Antioxidant, non-cytotoxic, anti-genotoxic, anti-carcinogenic effects of boric acid, the salt compound of boron has been reported before. Boronic acids have been approved for treatment by FDA and are included in drug discovery studies and pyridine boronic acids are a subclass of heterocyclic boronic acids used in drug design and discovery as substituted pyridines based on crystal engineering principles. The aim of our study was to determine the effect of 3-pyridinylboronic acid in rotenone-exposed zebrafish embryos, focusing on oxidant-antioxidant parameters and gene expression levels of nuclear factor erythroid 2-related factor 2 (Nrf2) target genes gclm, gclc, hmox1a, nqo1, and PD related genes, brain-derived neurotrophic factor, dj1, and tnfα. Zebrafish embryos were exposed to Rotenone (10 μg/l); Low Dose 3-Pyridinylboronic acid (100 μM); High Dose 3-Pyridinylboronic acid (200 μM); Rotenone + Low Dose-3-Pyridinylboronic acid (10 μg/l + 100 μM); Rotenone + High Dose-3-Pyridinylboronic acid (10 μg/l + 200 μM) in well plates for 96 h post-fertilization (hpf). Our study showed for the first time that 3-pyridinylboronic acid, as a novel sub-class of the heterocyclic boronic acid compound, improved locomotor activities, ameliorated oxidant-antioxidant status by decreasing LPO and NO levels, and normalized the expressions of bdnf, dj1, tnf⍺ and Nrf2 target genes hmox1a and nqo1 in rotenone exposed zebrafish embryos. On the other hand, it caused the deterioration of the oxidant-antioxidant balance in the control group through increased lipid peroxidation, nitric oxide levels, and decreased antioxidant enzymes. We believe that these results should be interpreted in the context of the dose-toxicity and benefit-harm relationship of the effects of 3-pyridinylboronic.

Indexed as

Neuroprotective AgentsParkinson DiseaseAnimalsAntioxidantsBoronBoronic AcidsNF-E2-Related Factor 2OxidantsOxidative StressPyridinesRotenoneZebrafish3-pyridinylboronic acidAntioxidantsBoronBoronic AcidsNeuroprotective AgentsNF-E2-Related Factor 2OxidantsPyridinesRotenone3-Pyridinylboronic acidParkinson’s diseaseRotenoneZebrafish embryos

Identifiers

PMID35142995
OpenAlexW4211089489

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.